Intrathecal cannabinoid-1 receptor agonist prevents referred hyperalgesia in acute acrolein-induced cystitis in rats.

We investigated the capacity of intrathecal arachidonyl-2'-chloroethylamide (ACEA), a cannabinoid-1 receptor (CB1R) agonist, to inhibit referred hyperalgesia and increased bladder contractility resulting from acute acrolein-induced cystitis in rats. 24 female rats were divided into 4 groups: 1) intrathecal vehicle/intravesical saline; 2) intrathecal vehicle/intravesical acrolein; 3) intrathecal ACEA/intravesical saline; and 4) intrathecal ACEA/intravesical acrolein. Bladder catheters were placed 4-6 days prior to the experiment. On the day of the experiment, rats were briefly anesthetized with isoflurane to recover the external end of the cystostomy catheter. After recovery from anesthesia, pre-treatment cystometry was performed, and mechanical sensitivity of the hindpaws was determined. Rats were again briefly anesthetized with isoflurane to inject ACEA or vehicle into the intrathecal space between L5-L6. Beginning 10 minutes after intrathecal injection, saline or acrolein was infused into the bladder for 30 minutes. Post-treatment cystometry and mechanical sensitivity testing were performed. Rats were euthanized, and bladders were collected, weighed, and fixed for histology. The intrathecal vehicle/intravesical acrolein group developed mechanical hyperalgesia with post-treatment mechanical sensitivity of 6 ± 0.3 g compared to pretreatment of 14 ± 0.4 g (p < 0.01). Pre- and post-treatment hind paw mechanical sensitivity was statistically similar in rats that received intrathecal ACEA prior to intravesical infusion of acrolein (15 ± 0.2 g and 14 ± 0.4 g, respectively). Acrolein treatment increased basal bladder pressure and maximal voiding pressure and decreased intercontraction interval and voided volume. However, intrathecal ACEA was ineffective in improving acrolein-related urodynamic changes. In addition, bladder histology demonstrated submucosal and muscularis edema that was similar for all acrolein-treated groups, irrespective of ACEA treatment. Intravesical saline had no effect on results of cystometry or mechanical sensitivity of the hind paws, regardless of intrathecal treatment. Intrathecal ACEA prevented referred hyperalgesia associated with acute acrolein-induced cystitis. However, in this experimental model, ACEA did not ameliorate the associated urodynamic changes. These findings suggest that pain arising from cystitis may be inhibited by activation of spinal CB1R but the acute local response of the bladder appeared to be unaffected by stimulation of spinal CB1R.

[1]  F. Montorsi,et al.  The fatty acid amide hydrolase inhibitor oleoyl ethyl amide counteracts bladder overactivity in female rats , 2014, Neurourology and urodynamics.

[2]  Y. Homma,et al.  Inhibition of peripheral FAAH depresses activities of bladder mechanosensitive nerve fibers of the rat. , 2014, The Journal of urology.

[3]  M. Casu,et al.  Pulmonary , gastrointestinal and urogenital pharmacology Evaluation of selective cannabinoid CB 1 and CB 2 receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis , 2014 .

[4]  C. Stief,et al.  Bladder function in a cannabinoid receptor type 1 knockout mouse , 2014, BJU international.

[5]  F. Montorsi,et al.  Spinal cord FAAH in normal micturition control and bladder overactivity in awake rats. , 2013, The Journal of urology.

[6]  J. Calixto,et al.  Antagonism of the transient receptor potential ankyrin 1 (TRPA1) attenuates hyperalgesia and urinary bladder overactivity in cyclophosphamide-induced haemorrhagic cystitis. , 2013, Chemico-biological interactions.

[7]  I. Katona,et al.  Endocannabinoid‐dependent plasticity at spinal nociceptor synapses , 2012, The Journal of physiology.

[8]  G. Benedek,et al.  The Effects of Peptide and Lipid Endocannabinoids on Arthritic Pain at the Spinal Level , 2012, Anesthesia and analgesia.

[9]  S. Petrosino,et al.  Spinal anandamide produces analgesia in neuropathic rats: Possible CB1- and TRPV1-mediated mechanisms , 2012, Neuropharmacology.

[10]  W. Bushman,et al.  Lidocaine prevents referred hyperalgesia associated with cystitis , 2009, Neurourology and urodynamics.

[11]  J. Henry,et al.  Physiological evidence of a postsynaptic inhibition of the tail flick reflex by a cannabinoid receptor agonist. , 2009, European journal of pharmacology.

[12]  G. Benedek,et al.  The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level , 2008, PAIN.

[13]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[14]  A. Dyson,et al.  Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat , 2005, Pain.

[15]  B. Cravatt,et al.  The endogenous cannabinoid system and its role in nociceptive behavior. , 2004, Journal of neurobiology.

[16]  C. Salio,et al.  Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord , 2002, Neuroscience.

[17]  W. Farquhar-Smith,et al.  Administration of Endocannabinoids Prevents a Referred Hyperalgesia Associated with Inflammation of the Urinary Bladder , 2001, Anesthesiology.

[18]  J. Harris,et al.  Activation of spinal cannabinoid 1 receptors inhibits C‐fibre driven hyperexcitable neuronal responses and increases [35S]GTPγS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats , 2000, The European journal of neuroscience.

[19]  A. Basbaum,et al.  Spinal cannabinoids are anti-allodynic in rats with persistent inflammation , 1999, Pain.

[20]  W. Campbell,et al.  Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). , 1999, The Journal of pharmacology and experimental therapeutics.

[21]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[22]  R. Rubin,et al.  Cyclophosphamide hemorrhagic cystitis. , 1966, The Journal of urology.